Beyond Ozempic: Novo Nordisk Plots Next Decade Growth with Bigger Pipeline, Slimmer Workforce
Novo Nordisk targets 2026-2030 growth, and unveils Phase 3 CagriSema results beating Eli Lilly's tirzepatide in weight loss trials.
Stocks · News reference
Eli Lilly Announces FDA Approval Of Inluriyo In Combination With Verzenio For Treatment Of Adults With ER+, HER2–, ESR1-Mutated Locally Advanced Or Metastatic Breast Cancer
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Trex Bio Files For Initial Public Offering; Applies To List Common Stock On Nasdaq Under Symbol 'TRXB'; Eli Lilly Indicates Interest In Purchasing Up To 19.9% Of Trex Bio Common Stock; Says J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow Are Underwriters To IPO
https://www.sec.gov/Archives/edgar/data/2139097/000119312526395671/ck0002139097-20260918.htm
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.